Sohanya Cheng
Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About Sohanya Cheng
The proxy statement of Karyopharm Therapeutics Inc. reports total compensation of $1,094,829 for Sohanya Cheng in fiscal 2024, including a base salary of $546,000. Disclosed compensation is on record for 3 fiscal years.
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
Karyopharm Therapeutics Inc. (KPTI)
Proxy statement
Start not stated–2025-04-14
Last confirmed by a filing; no departure on record
Company network
Recorded roles and call appearances connecting this person to public companies.
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2024 | Karyopharm Therapeutics Inc. (KPTI) | Chief Commercial Officer and Head of Business Development | $546,000 | $1,094,829 |
| 2023 | Karyopharm Therapeutics Inc. (KPTI) | Chief Commercial Officer and Head of Business Development | $513,688 | $1,193,414 |
| 2022 | Karyopharm Therapeutics Inc. (KPTI) | — | $457,333 | $2,612,718 |
Recent activity
No call appearances or filed executive changes recorded yet.